Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

Authors: Jones, SA  Scheller, J  Rose-John, S 
Citation: Jones SA, etal., J Clin Invest. 2011 Sep 1;121(9):3375-83. doi: 10.1172/JCI57158. Epub 2011 Sep 1.
Pubmed: (View Article at PubMed) PMID:21881215
DOI: Full-text: DOI:10.1172/JCI57158

The successful treatment of certain autoimmune conditions with the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the beta-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.

Annotation

Molecular Pathway Annotations
Objects Annotated

Additional Information

 
RGD Object Information
RGD ID: 5686839
Created: 2012-01-27
Species: All species
Last Modified: 2012-01-27
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.